ADMA Biologics News - August 2026
BlackRock's 16.5% Stake in ADMA Biologics Signals Big-Money Confidence, but Can a Plasma Drug Company Justify the Hype?
Shares of ADMA Biologics surged 9.2% to $10.20 on August 31, bucking a softer broader market, after BlackRock disclosed ownership of roughly 38.4 million...
🟢 ADMA Biologics is trading 9.21% up in pre-market after BlackRock disclosed a 16.5% stake
ADMA Biologics is trading 9.21% up in pre-market at $10.20 after BlackRock disclosed ownership of 38,355,684 shares, representing about 16.5% of the...
BlackRock acquires 16.5% stake in ADMA Biologics for $321 million
BlackRock Inc. disclosed a new investment in ADMA Biologics on August 27, 2026. The asset manager acquired 38,355,684 shares of the biotechnology firm during...
🟢 ADMA Biologics is trading 7.5% up in pre-market on positive Moderna and Merck Phase 3 results
ADMA Biologics is trading 7.5% up at $10.80, primarily on biotech-sector strength following positive Phase 3 personalized cancer-vaccine results from Moderna...
ADMA Biologics Surges 10% on a Profit Beat, but Can One Star Product Carry a Company With a Shrinking Second Act?
Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by...
ADMA Biologics Surges 10% on a Profit Beat, but Can One Star Product Carry a Company With a Shrinking Second Act?
Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by...
🟢 ADMA Biologics is trading 10% up today after stronger profitability despite revenue miss
ADMA Biologics is trading $10.19 (+9.99%) after second-quarter earnings on August 5, 2026, showed stronger profitability despite a slight revenue miss. •...
ADMA Biologics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect ADMA Biologics to report Q2 2026 revenue of $125.34 million and EPS of $0.16, as the stock trades near $8.46 against a median analyst price...